Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer

被引：0
|
作者：
Xuetian Gao
Ling Peng
Li Zhang
Kai Huang
Cuihua Yi
Bei Li
Xue Meng
Jisheng Li
机构：
[1] Shandong Cancer Hospital and Institute,Department of Radiation Oncology
[2] Shandong First Medical University and Shandong Academy of Medical Science,Department of Respiratory Disease
[3] Zhejiang Provincial People’s Hospital,Department of Oncology
[4] Yunyang County People’s Hospital,Department of Medical Oncology
[5] Qilu Hospital,undefined
[6] Cheeloo College of Medicine,undefined
[7] Shandong University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
Anlotinib; Small cell lung cancer; Efficacy; Survival; Adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2661 / 2671
页数：10
相关论文
共 50 条
  • [1] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Gao, Xuetian
    Peng, Ling
    Zhang, Li
    Huang, Kai
    Yi, Cuihua
    Li, Bei
    Meng, Xue
    Li, Jisheng
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2661 - 2671
  • [2] Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer
    Seto, Zenta
    Takata, Naoki
    Murayama, Nozomu
    Tokui, Kotaro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Inomata, Minehiko
    [J]. TUMORI JOURNAL, 2021, 107 (06): : 536 - 541
  • [3] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Gong, Jinhong
    Wan, Qian
    Shang, Jingjing
    Qian, Xiaodan
    Su, Dan
    Sun, Zhiqiang
    Liu, Guangjun
    [J]. ADVANCES IN THERAPY, 2021, 38 (10) : 5116 - 5126
  • [4] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Jinhong Gong
    Qian Wan
    Jingjing Shang
    Xiaodan Qian
    Dan Su
    Zhiqiang Sun
    Guangjun Liu
    [J]. Advances in Therapy, 2021, 38 : 5116 - 5126
  • [5] Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
    Wang, Jing
    Zhao, Yizhuo
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Yu, Hao
    Zhao, Yang
    Chen, Weiqiang
    Luo, Yi
    Wang, Xiuwen
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Liu, Zhujun
    Han, Baohui
    Li, Kai
    [J]. CANCER BIOLOGY & MEDICINE, 2018, 15 (04) : 443 - 451
  • [6] Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
    Yuan, Jing
    Cheng, Feng
    Xiao, Guodong
    Wang, Xiaofeng
    Fan, Huijie
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
    Wang, F.
    Jin, F.
    Wang, S.
    Zhu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S673 - S673
  • [8] Efficacy of Vinorelbine Monotherapy as Third- or Further-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
    Kang, Hyun
    Kim, Ju Ock
    Jung, Sung Soo
    Park, Hee Sun
    Chung, Chaeuk
    Park, Dongil
    Lee, Jeong Eun
    [J]. ONCOLOGY, 2019, 97 (06) : 356 - 364
  • [9] The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
    Zhai, Chongya
    Zhang, Xiaoling
    Ren, Lulu
    You, Liangkun
    Pan, Qin
    Pan, Hongming
    Han, Weidong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10
  • [10] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Fen Wang
    Feng Jin
    Boran Cheng
    Yue Zhang
    Qing Zhou
    Shubin Wang
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1721 - 1735
12345